Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

1. ENGOT-ov65/KEYNOTE-B96 trial combined pembrolizumab with paclitaxel and bevacizumab. 2. Significant improvement in median progression-free survival: 8.3 months vs 7.2 months with placebo. 3. Under FDA priority review as a treatment for platinum-resistant ovarian cancer. 4. Presenting results included high objective response rates and manageable safety profiles. 5. Study emphasizes chemotherapy's role in enhancing antitumor immunity for optimal outcomes.